From GlobeNewswire:

Keros Therapeutics, Inc. has just announced the pricing of 3,500,000 shares of common stock, at a public offering price of $40.00 per share. The gross proceeds are expected to be $140.0 million. The offering is being made pursuant to a shelf registration statement on Form S-3. Their lead protein therapeutic product candidate, KER-050 (elritercept), is being developed for the treatment of low blood cell counts, anemia, and thrombocytopenia, while their second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and cardiovascular disorders, and their third product candidate, KER-065, for the treatment of obesity and neuromuscular diseases. Investors can obtain more informations at the SEC’s website or from Goldman Sachs & Co.

Keros Therapeutics, Inc. is a biopharmaceutical company focused on, disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company has lead protein therapeutic product candidate, KER-050 (elritercept), being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with MF. Keros’ second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. The company has a risk assessment on their minimal operating history and historical losses, but they are confident that their product candidates will perform well and benefit patients.



Read more: Keros Therapeutics Announces Pricing of Upsized Public